Abstract 1184P
Background
An MCED blood test (Galleri®) has been in clinical use since April 2021. It is intended for screening adults aged 50-79 yrs. Using machine learning, this MCED test analyzes targeted methylation in cell-free DNA to detect a cancer signal and predict cancer signal origin (CSO). Individuals with suspected “false positive” results are offered a retest. Here we report early clinical experience with MCED retesting.
Methods
We analyzed likelihood of a subsequent cancer diagnosis in individuals with an initial MCED test result (Test 1) of cancer signal detected (CSD) and a negative initial diagnostic evaluation, followed by a second MCED test (Retest) within 3-6 mos for most.
Results
In a real-world evidence (RWE) cohort of ∼200,000 commercial MCED tests with ∼1800 CSD results, 159 individuals (69% male, mean age 67 yr [IQR: 60-76]) were identified who match the above criteria (Table). The mean time between blood draws was 5.4 mos [IQR: 3.8-6.1]. Of these patients, 31% (50/159) had a persistent CSD and 69% (109/159) had no cancer signal detected (NCSD) on Retest. Hematologic CSOs on Test 1 had statistically higher CSD on Retest (64%, 18/28) compared to solid tumor CSOs (24%, 32/131; p
Conclusions
Early RWE shows that persistent CSD on Retest is associated with a higher risk of cancer diagnosis, suggesting the need for close monitoring and/or additional diagnostic evaluation in these patients and the value of retesting. Patients with hematologic CSOs on Test 1 were more likely to have CSD on Retest than patients with solid cancer CSOs. No subsequent cancers have been diagnosed in patients with NCSD on Retest.
Clinical trial identification
Editorial acknowledgement
Writing and editorial assistance was provided by Neva C West, PhD (NeuroWest Solutions, Chicago, IL, USA).
Legal entity responsible for the study
Grail, Llc.
Funding
Grail, Llc.
Disclosure
C. Westgate: Financial Interests, Personal, Speaker, Consultant, Advisor: Grail Llc, Myriad; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca. O. Gordon: Financial Interests, Institutional, Research Funding: Grail Llc; Financial Interests, Personal, Advisory Role: Genetic Technologies Corp. M. Margolis, R. Jiang, E.A. Klein: Financial Interests, Personal, Full or part-time Employment: Grail Llc. Y. Oh, O. Venn, S. Leake, E. Hubbell, E.T. Fung, J. Venstrom, R.S. Shaknovich: Financial Interests, Personal, Full or part-time Employment, stock ownership in Illumina, Bristol Myers Squibb, Gilead, Baxter, and Bayer: Grail Llc. D. Broyles: Financial Interests, Personal, Speaker, Consultant, Advisor: Grail Llc, Cardiogiagnostics Holdings; Financial Interests, Personal, Ownership Interest: Caralyst; Financial Interests, Personal, Officer: Imperial Diagnostics. W. Jones, J. Ferrell: Financial Interests, Personal, Speaker, Consultant, Advisor: Grail Llc. All other authors have declared no conflicts of interest.
Resources from the same session
697P - The Empower Pathway overview: An innovative approach to delivering personalised care for testicular cancer survivors
Presenter: Robert Holwell
Session: Poster session 09
698P - Outcomes of patients with testicular germ cell tumors in Latin-America
Presenter: Saul Campos Gomez
Session: Poster session 09
699P - Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadectomy in Metastastic Seminoma) trial: Three year update
Presenter: Axel Heidenreich
Session: Poster session 09
701P - Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT)
Presenter: Hedyeh Ebrahimi
Session: Poster session 09
702P - Survival and related factors in testicular non-seminomatous patients undergoing high-dose chemotherapy and autologous stem cell transplantation: Experience of Turkey's highest volume transplantation center
Presenter: Musa Baris Aykan
Session: Poster session 09
703P - Survival of Hispanic germ cell tumor patients at a single academic institution vs. SEER
Presenter: Adam Kolawa
Session: Poster session 09
704P - Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study
Presenter: Christoph Oing
Session: Poster session 09
705P - Subsequent malignant neoplasms (SMN) in patients with germ cell tumor of the testis (TGCT): Implications on a genetic vs stem cell origin of cancers
Presenter: Sruthi Vellanki
Session: Poster session 09
706P - Stereotactic radiosurgery (SRS) in brain metastases (BMs) from non-seminomatous germ cell tumours (NSCGTs)
Presenter: Deep Chakrabarti
Session: Poster session 09